Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03745716
Title APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA

Additional content available in CKB BOOST